Biocon Limited. Q4 results show a revenue rise from 3019.7 to 3928.8 crores, a 30.11% increase in growth. EPS also rise from ₹-0.35 to ₹2.62, up by 648.57%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Biocon Ltd. shared its Q4 results on Tuesday. They earned 3928.8 crores in revenue this quarter, but that’s higher than the 3019.7 crores they made last quarter. The company’s growth increased by 30.11 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 313.2 crores, up from -41.8 crores in the previous quarter. Their quarter-to-quarter growth inclined by 649.28 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹2.62, which is an increase of 648.57% from the ₹-0.35 EPS in the previous quarter.
Also read: ☞ ” Kirloskar Industries Q4FY23 Results: Consolidated PAT of Rs 43.87 Cr “
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 11550.1 crores this year (2023), which is 37.56 percent higher than last year’s total revenue of 8396.7 crores.
This year’s PAT (Profit After Tax) is 462.7 crores, which is also 28.64% higher than last year’s PAT of 648.4 crores.
The EPS (Earnings Per Share) for this year is ₹3.88, which is 28.67% less than the EPS of ₹5.44 earned last year.
Biocon Share Dividend Announcement / Record Date:
The Board of Directors has declared a Final Dividend of ₹1.50 per Equity Share of Face Value of ₹5 each of the Company (30% of Face Value). Total Dividend for FY23 stood at ₹0.50 per Equity Share (Interim Dividend of ₹10 per Equity Share)
| Dividend | Record Date |
| ₹1.50 per Equity Share | 08/09/2023 |
About Biocon:
Biocon Limited is an Indian biopharmaceutical company headquartered in Bangalore. It was established by Kiran Mazumdar-Shaw in 1978. The company specializes in the production of generic active pharmaceutical ingredients, which are distributed in around 120 countries worldwide, including the United States and Europe.
Download Full PDF Q4 Results of Biocon: Click Here
For more of the Latest News, Click Here
One thought on “Biocon Q4FY23 Results: Consolidated PAT Rises to Rs 313.2 Cr”